Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen

Immunology and Cell Biology

Volumn 94, Issue 6, 2016, Pages 593-603

  Shklovskaya, Elena ^a,b   Terry, Alexandra M ^a,b   Guy, Thomas V ^a,b   Buckley, Adrian ^a,b,c   Bolton, Holly A ^a,b   Zhu, Erhua ^a,b   Holst, Jeff ^a,b   De St Groth, Barbara Fazekas ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GOSFORD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL KILLING; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ERADICATION; HOST; IMMUNOCOMPETENT CELL; LYMPH NODE; MELANOMA; MOLECULE; MOUSE; NONHUMAN; TH1 CELL; TRANSGENICS; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CELL MOTION; DISEASE MODEL; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SCID MOUSE; SKIN TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; INTERFERON-GAMMA; LYMPH NODES; MELANOMA; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; SKIN NEOPLASMS;

EID: 84959516502     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2016.14     Document Type: Article

References (50)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360
2. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, et al. How do CD4(+) T cells detect, and eliminate tumor cells that either lack or express MHC class II molecules?. Front Immunol 2014; 5: 174
3. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207: 651-667
4. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4+ T cells develop cytotoxic activity, and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207: 637-650
5. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992; 257: 548-551
6. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, et al. Distinct role of antigen-specific T helper type 1 (Th1), and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190: 617-627
7. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368
8. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22: 371-383
9. Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4(+), and CD8(+) T cells during the effector phase. J Exp Med 2010; 207: 2469-2477
10. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300: 337-339
11. Chamuleau ME, Ossenkoppele GJ, Van de Loosdrecht AA. MHC class II molecules in tumour immunology: prognostic marker, and target for immune modulation. Immunobiology 2006; 211: 619-625
12. Degenhardt Y, Huang J, Greshock J, Horiates G, Nathanson K, Yang X, et al. Distinct MHC gene expression patterns during progression of melanoma. Genes Chromosomes Cancer 2010; 49: 144-154
13. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975; 35: 218-224
14. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346-5354
15. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112: 362-373
16. Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, et al. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory, and terminally differentiated phenotype. J Exp Med 2012; 209: 2113-2126
17. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 1999; 96: 8633-8638
18. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-2199
19. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091-1098
20. Widera G, Burkly LC, Pinkert CA, Böttger EC, Cowing C, Palmiter RD, et al. Transgenic mice selectively lacking MHC Class II (I-E) antigen expression on B cells: an in vivo approach to investigate Ia gene function. Cell 1987; 51: 175-187
21. Berg LJ, Pullen AM, Fazekas de St Groth B, Mathis D, Benoist C, Davis MM. Antigen/MHC-specific T cells are preferentially exported from the thymus in the presence of their MHC ligand. Cell 1989; 58: 1035-1046
22. Bhayani H, Paterson Y. Analysis of peptide binding patterns in different major histocompatibility complex/T cell receptor complexes using pigeon cytochrome c-specific T cell hybridomas. Evidence that a single peptide binds major histocompatibility complex in different conformations. J Exp Med 1989; 170: 1609-1625
23. Shklovskaya E, Roediger B, Fazekas de St Groth B. Epidermal, and dermal dendritic cells display differential activation, and migratory behavior while sharing the ability to stimulate CD4+ T cell proliferation in vivo. J Immunol 2008; 181: 418-430
24. Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?. Nat Rev Immunol 2014; 14: 719-730
25. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190: 4899-4909
26. Smith AL, Wikstrom ME, Fazekas de St Groth B. Visualizing T cell competition for peptide/MHC complexes: a specific mechanism to minimize the effect of precursor frequency. Immunity 2000; 13: 783-794
27. Shklovskaya E, Fazekas de St Groth B. Severely impaired clonal deletion of CD4+ T cells in low-dose irradiated mice: role of T cell antigen receptor, and IL-7 receptor signals. J Immunol 2006; 177: 8320-8330
28. Kreiter S, Vormehr M, Van de Roemer N, Diken M, Lower M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520: 692-696
29. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12: 677-686
30. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth, and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1: 447-456
31. Bolton HA, Zhu E, Terry AM, Guy TV, Koh W-P, Tan S-Y, et al. Selective Treg reconstitution during lymphopenia normalizes DC costimulation, and prevents graft-versus-host disease. J Clin Invest 2015; 125: 3627-3641
32. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202: 907-912
33. Flament H, Alonso Ramirez R, Premel V, Joncker NT, Jacquet A, Scholl S, et al. Modeling the specific CD4+ T cell response against a tumor neoantigen. J Immunol 2015; 194: 3501-3512
34. Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T cells, and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 1994; 91: 5700-5704
35. Lundin KU, Hofgaard PO, Omholt H, Munthe LA, Corthay A, Bogen B. Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of antiidiotypic antibodies. Blood 2003; 102: 605-612
36. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8, and CD4 responses in the eradication of solid tumors. Cancer Res 1999; 59: 1071-1079
37. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RBhigh, and CD45RBlow CD4+ T cells are important for the balance between protective, and pathogenic cell-mediated immunity. J Exp Med 1994; 179: 589-600
38. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma, and lymphocytes prevent primary tumour development, and shape tumour immunogenicity. Nature 2001; 410: 1107-1111
39. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494: 361-365
40. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10: 294-298
41. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490: 412-416
42. Jensen SM, Twitty CG, Maston LD, Antony PA, Lim M, Hu HM, et al. Increased frequency of suppressive regulatory T cells, and T cell-mediated antigen loss results in murine melanoma recurrence. J Immunol 2012; 189: 767-776
43. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344: 641-645
44. Girgis L, Davis MM, Fazekas de St Groth B. The avidity spectrum of T cell receptor interactions accounts for T cell anergy in a double transgenic model. J Exp Med 1999; 189: 265-277
45. Linnemann C, Van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015; 21: 81-85
46. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 2014; 6: 254ra128
47. Fazekas de St Groth B, Patten PA, Ho WY, Rock EP, Davis MM. In: An analysis of T cell receptor-ligand interaction using a transgenic antigen model for T cell tolerance, and T cell receptor mutagenesis. Alt FW, Vogel HJ (eds). Molecular Mechanisms of Immunological Self-Recognition. Academic Press: San Diego, CA, USA, 1992, pp 123-127
48. Brooks A, Hartley S, Kjer-Nielson L, Perera J, Goodnow CC, Basten, et al. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme. Proc Natl Acad Sci USA 1991; 88: 3290-3294
49. Holst J, Szymczak-Workman AL, Vignali KM, Burton AR, Workman CJ, Vignali DA. Generation of T-cell receptor retrogenic mice. Nat Protoc 2006; 1: 406-417
50. Shklovskaya E, O'Sullivan BJ, Ng LG, Roediger B, Thomas R, Weninger W, et al. Langerhans cells are precommitted to immune tolerance induction. Proc Natl Acad Sci USA 2011; 108: 18049-18054